
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Laboratory of Cancer Cell Biology and Genetics, Department of Human Oncology [C. A. S., A. A. P., L-P. G., K. A. B., S. G. S., L. E. J., L. S., S. E. S.], Departments of Human Genetics [S. E. S.], Human Oncology [R. J., T. J., D. H., N. W.], and Pathology and Laboratory Medicine [J. F. S.], Allegheny University of the Health Sciences, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212
Human solid tumors develop multiple genetic abnormalities that accumulate progressively in individual cells during the course of tumor evolution. We sought to determine whether there are specific sequences of occurrence of these progressive evolutionary changes in human breast cancers by performing correlated cell-by-cell measurements of cell DNA content, p53 protein, Her-2/neu protein, and ras protein by multiparameter flow cytometry in 56 primary tumor samples obtained at surgery. In addition, p53 allelic loss and Her-2/neu gene amplification were determined by fluorescence in situ hybridization in cells from the same samples. We reasoned that if there is a specific order in which genetic changes occur, the same early changes would be found consistently in the cells with the fewest abnormalities. We reasoned further that late-developing abnormalities would not occur alone in individual cells but would almost always be found together with the early changes inherited by the same cells. By these criteria, abnormalities involving p53 generally occurred early in the course of development of invasive breast cancers, whereas ras protein overexpression was found to be a late-occurring phenomenon. Within individual tumors, cellular p53 overexpression was often observed alone in individual cells, whereas ras protein overexpression was rarely observed in the absence of p53 overexpression and/or Her-2/neu overexpression in the same cells. Furthermore, the intracellular level of each abnormally expressed protein was found to increase progressively as new abnormalities were acquired. Infiltrating ductal carcinomas exhibited characteristic phenotypic patterns in which p53 allelic loss and/or p53 protein overexpression, Her-2/neu amplification and/or overexpression, aneuploidy, and ras overexpression accumulated within individual cells. However, this pattern was not a prominent feature of lobular breast cancers. All six lobular breast cancers studied were diploid. p53 allelic loss and/or early p53 overexpression, and late ras cooverexpression in the same cells were less common in lobular breast cancers than in infiltrating ductal carcinomas. Although Her-2/neu overexpression was a common finding in lobular breast cancers, Her-2/neu amplification was not observed in these tumors.
This article has been cited by other articles:
![]() |
J. A. Sparano, S. Moulder, A. Kazi, L. Vahdat, T. Li, C. Pellegrino, P. Munster, M. Malafa, D. Lee, S. Hoschander, et al. Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide J. Clin. Oncol., July 1, 2006; 24(19): 3013 - 3018. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Bussey, K. Chin, S. Lababidi, M. Reimers, W. C. Reinhold, W.-L. Kuo, F. Gwadry, Ajay, H. Kouros-Mehr, J. Fridlyand, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther., April 1, 2006; 5(4): 853 - 867. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Tso, W. A. Freije, A. Day, Z. Chen, B. Merriman, A. Perlina, Y. Lee, E. Q. Dia, K. Yoshimoto, P. S. Mischel, et al. Distinct Transcription Profiles of Primary and Secondary Glioblastoma Subgroups Cancer Res., January 1, 2006; 66(1): 159 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Shackney, C. A. Smith, A. Pollice, K. Brown, R. Day, T. Julian, and J. F. Silverman Intracellular Patterns of Her-2/neu, ras, and Ploidy Abnormalities in Primary Human Breast Cancers Predict Postoperative Clinical Disease-Free Survival Clin. Cancer Res., May 1, 2004; 10(9): 3042 - 3052. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Doisneau-Sixou, P. Cestac, S. Chouini, J. S. Carroll, A. D. Hamilton, S. M. Sebti, M. Poirot, P. Balaguer, J.-C. Faye, R. L. Sutherland, et al. Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells Endocrinology, March 1, 2003; 144(3): 989 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Dunham, H. Badrane, T. Ferea, J. Adams, P. O. Brown, F. Rosenzweig, and D. Botstein Characteristic genome rearrangements in experimental evolution of Saccharomycescerevisiae PNAS, December 10, 2002; 99(25): 16144 - 16149. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ma, D. J. Webb, M. Jo, and S. L. Gonias Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells J. Cell Sci., March 11, 2002; 114(18): 3387 - 3396. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ottoboni, A. Crippa, C. Falugi, and P. Russo Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations Mutagenesis, September 1, 2001; 16(5): 423 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Blackshear Genetically Engineered Rodent Models of Mammary Gland Carcinogenesis: An Overview Toxicol Pathol, January 1, 2001; 29(1): 105 - 116. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |